Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vraylar (cariprazine) for the Treatment of Bipolar Disorder and Schizophrenia

Drug (brand/generic)

Vraylar (cariprazine)

Company/Licensee

Gedeon Richter/Allergan

Therapy Class

Atypical antipsychotic agent

Current Indication

Bipolar I disorder and schizophrenia

Market Sector

CNS

Development Status

Approved in the US
Expand

Go Top